Tianda Pharma Interim Results 2021
Significant business growth achieved R&D efforts and BD initiatives to continue
HONG KONG, Nov 26, 2021 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharma or the Group, stock code: 0455.HK) is pleased to announce its interim results for the six months ended 30 September 2021 (the "Reporting Period"). During the Reporting Period, all three business segments of the Group recorded significant business growth, with the total revenue reaching HK$236.5 million, representing an increase of 26.2% year on year (YOY). The Group's financial position remains strong, with net assets of HK$777.0 million, and bank deposits, cash and bank balances of HK$202.2 million, as well as unutilised bank loan facilities of HK$77.8 million as at 30 September 2021. Such strong financial position provides the Group with sufficient financial resources to support its steady business development.
The Chinese medicine business recorded revenue of HK$58.0 million, representing an increase of 64.2% YOY. In line with the national policies supporting the Traditional Chinese Medicine (TCM) industry, the Group has spent over five years establishing a complete TCM industrial chain layout, covering the trading of Chinese medicinal materials, production of TCM decoction pieces, R&D of TCM, a comprehensive Chinese medicine product portfolio, as well as domestic and overseas procurement and marketing network. The Pharmaceuticals and medical technologies business recorded revenue of HK$174.9 million, representing an increase of 16.6% YOY. The Group's major product, Tuoping Valsartan capsules, a medicine for cardio-cerebrovascular disease, is the No. 1 product of its kind in China in terms of sales volume. The Group is seizing the opportunity of the success of Tuoping in securing first place in China's Third Round of Centralized Drug Procurement with Target Quantity to further increase its sales volume. The Group's new R&D and production base in Jinwan, Zhuhai, scheduled to commence production in January next year, is poised to become a pharmaceutical and health industry base with high standard, quality and efficiency. The Medical and healthcare service business recorded revenue of HK$3.6 million, representing an increase of 79.5% YOY. During the Reporting Period, the Group opened a TDMall with a renowned Chinese medicine expert by using an equity investment cooperation model for the first time. The equity investment cooperation model will become an important means for the rapid expansion of TDMalls. The Group is also accelerating the development of a cloud technology based Chinese medicine platform "TDMall on Cloud" to provide services such as online intelligent consultation, online medical treatment and comprehensive health e-commerce to the public. Together, this online initiative and the physical TDMalls will help to develop "TDMall" into the leading brand of Chinese medical clinic.
The Group has continued to increase innovation and R&D efforts, with steady progress made in development of Classic Ancient Prescriptions, cardio-cerebrovascular drugs, pediatric drugs, and diabetes drugs, etc. Meanwhile, BD initiatives have been increased as well to integrate organically with R&D activities to improve the quality and quantity of R&D projects in its pipeline through external introduction, independent and collaborative R&D. This is to further enrich the product lines while identifying cutting-edge technological and product opportunities globally, so as to help grow the Group's business on the whole.
China has proposed in the "14th Five-Year Plan and the Long-Range Objectives Through the Year 2035" to promote the inheritance and innovation of TCM, to emphasize on the equal importance and complementary advantages of Chinese and Western medicine, and to vigorously develop the Chinese medicine business, providing favorable policy support for the Group's business development. The Group will continue to implement the "Three Developments" strategy, deepening the layout of all three business segments and actively evaluating merger and acquisition opportunities to accelerate the pace of business growth and scale expansion, so as to strive to become a leading pharmaceutical enterprise that sets its footholds in China while expanding its presence worldwide to make greater contribution to safeguarding the health of mankind.
About Tianda Pharmaceuticals Limited Tianda Pharmaceuticals Limited is engaged in the development of Chinese medicine business as foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services, committed to become a leading pharmaceutical enterprise that sets its footholds in China while expanding its presence worldwide.
For enquiries Tianda Pharmaceuticals Limited Investor Relations Department Phone: +852 2545 3313 Email: ir@tianda.com
Source: Tianda Pharmaceuticals Limited Sectors: Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Press Release
 New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China May 28, 2025 17:45 JST
|  GK Software becomes a Fujitsu company May 28, 2025 15:33 JST
|  Construction Begins on New Toyota Tokyo Head Office in Shinagawa, to Open in FY2030 May 27, 2025 14:31 JST
|  JCB partners with PayXpert to expand in-store card acceptance for international shoppers and travellers coming to Europe and in the UK May 27, 2025 12:00 JST
|  JCB Collaborates with Noage International to Expand Advanced Medical Tourism Program in Japan for Affluent Indonesians May 27, 2025 10:00 JST
|  Ministry of Energy of Uzbekistan and MHI Sign MOU to Conduct Joint Study of Decarbonization Strategy for Uzbekistan May 27, 2025 09:49 JST
| Fujitsu launches second corporate venture capital fund to drive innovation and achieve a sustainable society May 26, 2025 18:27 JST
|  Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan May 23, 2025 17:29 JST
|  Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements May 23, 2025 13:36 JST
|  NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework May 23, 2025 13:35 JST
|  Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India May 23, 2025 12:17 JST
|  Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production May 23, 2025 11:32 JST
|  Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software May 23, 2025 10:51 JST
|  MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV May 22, 2025 13:35 JST
|  Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 May 21, 2025 15:00 JST
|  New RAV4 Makes World Premiere in Japan May 21, 2025 14:09 JST
|  Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer May 21, 2025 14:00 JST
|  MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines May 20, 2025 13:51 JST
|  MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT May 19, 2025 16:14 JST
|  Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro May 16, 2025 17:21 JST
|
More Latest Release >>
|